All News

Tarlatamab plus chemo/IO showed a 71% objective response rate and promising safety for patients with ES-SCLC in the DeLLphi-303 study.

Giredestrant plus everolimus doubled the ORR and prolonged the DOR in patients with ER-positive, HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor.

The AFSOS-Unicancer QUALIOR study did not meet its primary end point among patients with metastatic cancer.

Fruquintinib plus sintilimab significantly enhanced PFS in advanced RCC offering a promising second-line treatment option.

Pimicotinib shows promising long-term efficacy and safety for treating tenosynovial giant cell tumor, offering significant patient benefits in a recent trial.

Lenvatinib and everolimus significantly enhanced progression-free survival in metastatic clear cell RCC compared with cabozantinib, despite higher toxicity rates.

Osimertinib plus chemotherapy significantly improved overall survival in EGFR-mutated NSCLC, outperforming monotherapy across various prognostic factors.

Updated results from SunRISe-4 support further investigation of the gemcitabine intravesical system plus cetrelimab in MIBC.

A numerically greater response rate with regorafenib/nivolumab may encourage a search for more non-chemotherapy combinations for gastric cancer.

Adjuvant ribociclib plus aromatase inhibitors significantly improved invasive disease-free survival in early breast cancer, as shown in the NATALEE trial.

Data from monarchE showed an OS benefit with abemaciclib-based therapy that was consistent across prespecified patient subgroups.

A survival analysis stratified by demographic and clinical characteristics revealed an OS benefit was observed with across key subgroups.

Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.

Meta: Safety outcomes, including the treatment-related AEs and AEs leading to treatment discontinuation, were consistent with or without lenvatinib in ESCC.

Data from POTOMAC support durvalumab plus BCG and induction and maintenance therapy as a new treatment option in BCG-naive, high-risk NMIBC.

New findings reveal that adding durvalumab to neoadjuvant chemotherapy does not enhance HRQOL in muscle-invasive bladder cancer patients.

Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.

Using multiparametric MRI for initial staging, then cystoscopic biopsy, improves bladder cancer-specific survival compared with transurethral resection of bladder tumor staging.

Alectinib shows promising long-term survival benefits over crizotinib for advanced ALK-positive NSCLC, highlighting significant clinical advancements.

Venetoclax with bortezomib and dexamethasone led to a median PFS of 23.4 months compared with 11.4 months with placebo in patients with R/R MM.

Updated safety findings may support the ARASAFE regimen as a potential standard of care in metastatic hormone-sensitive prostate cancer.

Sevabertinib monotherapy was deemed tolerable across various cohorts of patients who were pretreated and treatment-naïve with HER2-mutant advanced NSCLC.

Results from the Beamion LUNG-1 study showed that first-line zongertinib yielded continued benefit for patients with HER2-mutated NSCLC.

Two hematologic oncologists defined rare lymphomas and highlighted challenges and recent developments associated with these disease types.

Updated results from CheckMate 274 support adjuvant nivolumab as a standard of care for patients with high-risk muscle-invasive urothelial carcinoma.

The safety profile of the atezolizumab with Bacillus Calmette-Guérin in NMIBC was consistent with that of each individual agent.

Proactive disclosure of information by clinical social workers in oncology may help equip patients to handle difficult aspects of cancer treatment.

The safety profile of durvalumab after radiotherapy was consistent with durvalumab after chemoradiotherapy among those with unresectable stage III NSCLC.

In lower- and middle-income countries, accessibility, cost, and talent are obstacles to broadly implementing cellular therapeutics into cancer care.

Investigators plan to present detailed findings from the MajesTEC-3 study at a future medical conference and share them with regulatory authorities.